1. Overview
Chromogranin A (CgA) is an acidic glycoprotein, also known as Parathyroid secretory protein 1. It is widely expressed by neuroendocrine cells and is located within secretory vesicles of neurons and endocrine cells, including the secretory granules of pancreatic islet beta cells. In humans, Chromogranin A is encoded by the CHGA gene.
CgA is colocalized within storage granules and is co-released along with neuropeptides such as neuropeptide Y (NPY) and catecholamines. It functions as an important tumor marker, particularly for neuroendocrine tumors (NETs). Circulating levels of Chromogranin A are typically increased during conditions of stress and hypoxia.
Clinically, Chromogranin A testing is used to diagnose neuroendocrine tumors at various anatomical locations, estimate prognosis, and monitor response to treatment. Testing may be performed when symptoms suggest a neuroendocrine tumor or when a possible NET is incidentally detected during imaging studies or surgery for unrelated conditions. Chromogranin-A.pptx
2. Symptoms
Chromogranin A itself does not cause symptoms; rather, elevated levels reflect the presence or activity of underlying neuroendocrine tumors or associated conditions. Symptoms depend on the tumor location and hormonal activity. Neuroendocrine tumors commonly originate in the small intestine, pancreas, lung-bronchial system, colon, rectum, thyroid, adrenal glands, ovary, or cervix.
Clinical manifestations may arise due to hormone secretion, tumor burden, or metastatic disease, with common metastatic spread involving the liver, lungs, and bones. Elevated CgA levels may also be detected in asymptomatic patients when a neuroendocrine tumor is discovered incidentally during imaging or surgical procedures.
3. Causes
Elevated Chromogranin A levels are commonly seen in neuroendocrine malignancies such as pancreatic cancer, prostate cancer, pheochromocytoma, carcinoid tumors, gastrinoma, neuroendocrine tumors of the small intestine, and medullary carcinoma of the thyroid.
CgA levels may also rise in several non-cancerous conditions, including renal failure, liver failure, pregnancy, hypertension, and hypergastrinemia of any cause. Treatment with proton pump inhibitors is a known cause of increased Chromogranin A levels.
Abnormally elevated results often require confirmation and further evaluation through repeat testing, radiological investigations such as ultrasound or CT scan, additional tumor marker tests, and invasive diagnostic procedures such as endoscopy, fine-needle aspiration cytology (FNAC), or biopsy when a mass is identified.
4. Risk Factors
Risk factors associated with elevated Chromogranin A levels include the presence of neuroendocrine tumors, conditions causing hypergastrinemia, impaired renal or liver function, and physiological states such as pregnancy. Use of proton pump inhibitors significantly increases CgA levels and may lead to false-positive results.
Tumor characteristics also influence test interpretation. Low proliferative index tumors may not show elevated circulating Chromogranin A. Rapidly proliferating, poorly differentiated neuroendocrine tumors may lose their typical secretory granules and release smaller amounts of CgA, leading to false-negative results. Therefore, reliance on Chromogranin A alone without clinical correlation may be misleading.
5. Prevention
There is no direct prevention for elevated Chromogranin A levels; however, accurate testing and interpretation are essential to avoid misdiagnosis. Proper patient preparation and appropriate sample collection help reduce analytical errors. Blood samples should be collected in plain red-capped tubes, with serum separated as early as possible. A minimum of 0.5 ml serum should be submitted, and samples should preferably be sent in a frozen state. Room temperature samples remain stable for up to seven days.
Gel tubes should not be used, and grossly hemorrhagic, moderately lipemic, or icteric samples are unsuitable for analysis due to the risk of faulty results. Interpretation of Chromogranin A levels should always be correlated with clinical findings, imaging studies, and other laboratory investigations. In certain cases, the marker may be useful only in conjunction with immunohistochemical techniques rather than as a circulating marker alone.
